|
End-of-day quote
Taipei Exchange
19/08/2026
|
5-day change | 1st Jan Change | ||
| 939.00 TWD | +4.92% |
|
0.00% | +136.52% |
| 14/08 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 28/04 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 7.78TCr 245.61Cr 211.64Cr 198.43Cr 181.14Cr 341.24Cr 23TCr 342.33Cr 2.35TCr 918.55Cr 12TCr 922.14Cr 902.07Cr 39TCr | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 6.15TCr 194.23Cr 167.37Cr 156.92Cr 143.25Cr 269.86Cr 19TCr 270.72Cr 1.86TCr 726.4Cr 9.37TCr 729.24Cr 713.37Cr 31TCr | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +4.92% | ||
| Current month | +37.89% | ||
| 1 month | +60.79% | ||
| 3 months | +149.40% | ||
| 6 months | +129.87% | ||
| Current year | +136.52% |
| 1 month | 547 |  | 969 |
| Current year | 331 | | 969 |
| 1 year | 149 | | 969 |
| 3 years | 70 | | 969 |
| 5 years | 70 | | 969 |
| 10 years | 27 | | 969 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 01/06/2016 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 25/07/2022 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 13/10/2016 |
Cheng Chi Wang
BRD | Director/Board Member | - | 27/06/2024 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 27/09/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.92% | 0.00% | +517.76% | +630.74% | 245.61Cr | |
| -0.13% | -6.44% | +60.34% | +112.06% | 1,04700Cr | |
| +0.85% | -0.81% | +51.29% | +63.13% | 65TCr | |
| -1.03% | -3.58% | +21.43% | +73.10% | 45TCr | |
| -1.46% | -4.50% | +37.80% | +37.41% | 35TCr | |
| -0.72% | -2.89% | +22.32% | +36.62% | 29TCr | |
| -1.19% | -2.21% | +1.53% | +10.79% | 25TCr | |
| -1.05% | -1.57% | +50.30% | +66.55% | 23TCr | |
| +0.08% | -1.78% | -17.64% | -54.36% | 20TCr | |
| -2.14% | -0.30% | +28.95% | +86.27% | 18TCr | |
| Average | -0.19% | -1.75% | +77.41% | +106.23% | 36.62TCr | |
| Weighted average by Cap. | -0.46% | -3.45% | +38.49% | +65.38% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -74Cr -2.35Cr -2.03Cr -1.9Cr -1.73Cr -3.27Cr -224.63Cr -3.28Cr -23Cr -8.79Cr -113.39Cr -8.82Cr -8.63Cr -375.99Cr | -136.28Cr -4.3Cr -3.71Cr -3.48Cr -3.17Cr -5.98Cr -411.33Cr -6Cr -41Cr -16Cr -207.64Cr -16Cr -16Cr -688.5Cr |
| Net Debt | -517.43Cr -16Cr -14Cr -13Cr -12Cr -23Cr -1.56TCr -23Cr -156.63Cr -61Cr -788.34Cr -61Cr -60Cr -2.61TCr | -1.63TCr -51Cr -44Cr -42Cr -38Cr -71Cr -4.91TCr -72Cr -492.49Cr -192.15Cr -2.48TCr -192.9Cr -188.71Cr -8.22TCr |
Employees
-
Sector
Pharmaceuticals
Calendar
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
